Many people reach a point where they and their prescriber decide it is time to reduce or stop a medication. Doing that safely takes structure, and one resource has become a key reference for that structure: the Maudsley Deprescribing Guidelines. The Guidelines, written by a psychiatrist and a pharmacist working with the Maudsley Hospital and King’s College London and published in 2024, offer a framework for tapering antidepressants, benzodiazepines, gabapentinoids and z-drugs gradually. They were developed to help clinicians and patients manage the process together, minimizing the risk and severity of withdrawal symptoms. For readers of this site, their treatment of benzodiazepines and z-drugs is especially relevant.
What are the Maudsley Deprescribing Guidelines?
The Maudsley Deprescribing Guidelines are a practical clinical reference for the gradual reduction of four groups of medications: antidepressants, benzodiazepines, gabapentinoids and z-drugs. They are not a guide to every psychiatric medication. Rather than abrupt discontinuation, which can cause significant distress and discomfort, the Guidelines emphasize a slow, hyperbolic tapering schedule. The core principle is that dose reductions need to become smaller and smaller as the total dose gets lower. This reflects the way these medications interact with receptors in the brain: at lower doses, each milligram carries proportionally more effect. The Guidelines pair drug-specific tapering guidance with practical advice on managing withdrawal symptoms and with support for shared decision-making between patient and prescriber. The same principle of patient control is the subject of this site’s article on patient-directed tapering.
For benzodiazepines and z-drugs, the Guidelines apply that receptor reasoning directly. Because a small dose still occupies a large share of the receptors it acts on, the last few milligrams are the ones that call for the smallest cuts, and the Guidelines describe liquid preparations or small-strength tablets as the practical way to make those final steps. The pace is set by symptoms rather than by a calendar: a reduction that produces more than tolerable symptoms is a signal to hold or to make the next step smaller. None of this contradicts the Ashton Manual. The Manual itself moves to 1 mg and then 0.5 mg diazepam reductions as the dose falls, and says the best judge of the pace is the person withdrawing; the Guidelines put a receptor-occupancy explanation under that older advice.
How does a Maudsley-style taper work?
For anyone considering a medication reduction, the process always begins with a conversation with the prescribing clinician.
- Shared decision-making: The first step is a collaborative discussion of the benefits and risks. Personal goals, lifestyle, and treatment history are all important factors.
- Personalized tapering plan: Using the Guidelines, the clinician can build a tapering schedule suited to the individual. The Maudsley approach is not one-size-fits-all; it is about finding a pace the body can comfortably adapt to.
- Slow and steady reduction: The plan involves very gradual dose reductions over an extended period. This may mean liquid formulations or smaller-dose tablets to achieve the precise reductions recommended.
- Symptom monitoring and support: Throughout the process, patient and prescriber watch for withdrawal symptoms, and the plan adjusts when they appear. A reliable support system makes the whole process steadier.
The Manual’s own stepwise method is described in this site’s article on the Ashton Protocol.
Why a guided approach matters
Undertaking medication changes without a clear plan is risky, and stopping a benzodiazepine abruptly is the riskiest course of all. If a seizure or any other medical emergency occurs, call emergency services. The deprescribing guidelines provide the essential structure: they give patients solid information and clinicians a reliable framework, a partnership that puts the patient’s wellbeing first. The framing matters as much as the schedule. A person who has become physically dependent on a medication taken as prescribed has a medical condition, not addiction, and gradual deprescribing, rather than an addiction program, is the appropriate response. For a sense of how gradual reduction schedules look in practice, the taper calculators on this site illustrate stepwise plans, including the Ativan, benzodiazepine, Klonopin, Xanax, and alprazolam taper calculators.
Frequently asked questions about the Maudsley Deprescribing Guidelines
What is the Maudsley deprescribing method?
The Maudsley deprescribing method is a patient-centered approach to safely stopping antidepressants, benzodiazepines, gabapentinoids and z-drugs. It uses a gradual, hyperbolic tapering schedule to help minimize withdrawal symptoms during the process.
Is Maudsley deprescribing evidence-based?
Yes. The Guidelines were written by a psychiatrist and a pharmacist working with the Maudsley Hospital and King’s College London, were published in 2024, and are grounded in clinical evidence and pharmacological principles, providing a careful framework for medication tapering.
How long does the Maudsley deprescribing process usually take?
The duration varies greatly among individuals, often taking several months or even years. The pace depends on the specific medication, the dosage, and the person’s response to the tapering process.
Can Maudsley deprescribing reduce withdrawal symptoms?
Yes. The central goal of the deprescribing guidelines is to minimize the severity of withdrawal symptoms through a slow, gradual dose reduction schedule tailored to the individual.
This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.
